Avinash Chaudhari, Amar Kulkarni, Mehak Trikha, Dinesh Gupta


INTRODUCTION: The Cardio Renal Anemia syndrome is a process involving the deterioration of heart
and kidney function linked with worsening anemia. Hyperphosphatemia is crucial indicator of poor
prognosis in cardio renal anemia syndrome. Ferric citrate has proven to be effective in reducing serum phosphorus and
increasing iron stores and hemoglobin in individuals with non-dialysis-dependent CKD who have iron-deciency anemia.
MATERIALS AND METHODS: After the approval of EC, this prospective study was conducted in D.Y Patil Hospital Navi
Mumbai. 50 patients were enrolled in the study and randomized into two treatment groups- one group receiving oral ferric
citrate and other ferrous fumarate.
RESULTS: Out of 50 patients, 18 (36%) were females and 32 (64%) were male. Most common sub type of CRAS was type 2
comprising of 25 patients (50%). The rise in mean biochemical parameters in ferric citrate group at week 52 were statistically
signicant as compared to baseline. Serum phosphate levels were reduced towards normal level in ferric citrate group at week
52, as compared to in ferrous fumarate group at same time point in the study(p<0.05).
CONCLUSION: The present study has shown ferric citrate to be superior to ferric fumarate in improving the hemoglobin, iron,
RBC indices and as a phosphate binder in patients with CRAS.


Cardiorenal anemia syndrome, phosphate, ferric citrate

Full Text:



Nand N, Giri K, Jain D. Role of Ferric Citrate in Hyperphosphatemia and Iron Deficiency Anemia in Non Dialysis CKD Patients. J Assoc Physicians India. 2019 Apr; 67(4):53-56.

Silverberg D, Wexler D, Blum M. The correction of anemia in severe resistant heart failure with erythropoietin and intravenous iron prevents the progression of both the heart and renal failure and markedly reduces hospitalization. Clin nephrol. 2002; 58(1):37 – 45.

Silverberg D, Wexler D, Blum. The interaction between heart failure, renal failure and anemia – the cardio renal anemia syndrome. Blood Purify. 2004; 22(3):277 – 84.

Bilal B A, Nida N, Khalid M, Chirajit S. Cardiorenal Syndrome Type I A-A Study of its Incidence, Risk Factors, Laboratory Parameters and Outcome. J Cardiol & Cardiovasc Ther. 2019; 14(3): 555887. DOI: 10.19080/JOCCT.2019.14.555887.

Lu K, Kearney L, Hare D. Cardiorenal anemia syndrome as a prognosticator for death in heart failure. Am J Cardiol. 2013; 111(8): 1187-1191.

Fishbane S, Spinowitz B . Update on Anemia in ESRD and Earlier Stages of CKD: Core Curriculum 2018. Am J Kidney Dis 2018; 71:423-3.

Iain C, Macdougall AJ, Bircher, Kai-UweEckardt, Gregorio T, Obrador Carol A, et al. Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney International 2016; 89:28-39.

ClinicalTrials.gov.in [Internet]. Bethesda (MD): National Library of Medicine (US). 2016 September 21. Identifier NCT 02888171, Impact of ferric citrate vs ferrous sulfate on iron parameters and hemoglobin in individuals with CKD and iron deficiency; 2017 March 22 [cited 2017 October 18] Available from : https://clinicaltrials.gov/ct2/show/NCT02888171.

Lee C, Wu I, Chiang S, et al. Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: multi center, randomized, double-blind, placebo-controlled study. J Nephrol. 2014; 28(1): 105-13.

Yokoyama K, Hirakata H, Akiba T, et al. Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients: results of a randomized, double-blind, placebo-controlled trial Am J Nephrol. 2012;36(5): 478-487.

Shah HR, Singh NP, Aggarwal NP, Singhania D, Kumar A. Cardiorenal Syndrome: Clinical Outcome Study. J Assoc Physicians India. 2016 Dec; 64(12):41-46.

Chertow GM, Block GA, Neylan JF, Pergola PE, Uhlig K, Fishbane S. Safety and efficacy of ferric citrate in patients with non dialysis-dependent chronic kidney disease. PLoS One. 2017 Nov 29;12(11):e0188712.

Panicker N, Hridya A, Prabhu R. Comparison of Efficacy and Safety Profile of Oral Iron Formulations in Patients with Iron Deficiency Anemia. Int. J. Pharm. Sci. Rev. Res. 2016; 41(2): 248-252

Hiratsuka M, Koyama K, Sengo K, Yamamoto J, Narita A, Ito C, et al. Long-term iron accumulation in dialysis patients treated with ferric citrate hydrate: a single-center, 80-week retrospective study in Japan. Renal Replacement Therapy 2017; 3:37:1

Ospina M, Holguín M, Escobar D, Restrepo. Importance of hyperphosphatemia in chronic kidney disease, how to avoid it and treat it by nutritional measures. Rev. Colomb. Nefrol. 2017;4(1): 24 – 41.

Ganz T, Bino A, Salusky I. Mechanism of Action and Clinical Attributes of Auryxia ® (Ferric Citrate). Drugs 2019; 79:957–968.

Al-Atrakji MQ. The effects of ferrous sulfate as an iron supplement on ejection fraction in patients with iron deficiency anemia associated with decompensated heart failure. Mustansiriya Med J 2018;17:22-8

Pinto-Sietsma SJ, Navis G, Janssen WM, de ZD, Gans RO, de Jong PE. A central body fat distribution is related to renal function impairment, even in lean subjects. Am J Kidney Dis. 2003;41:733-741.


  • There are currently no refbacks.